Tags

Type your tag names separated by a space and hit enter

Hormonal management of migraine associated with menses and the menopause: a clinical review.
Headache. 2007 Feb; 47(2):329-40.H

Abstract

OBJECTIVE

This article reviews hormonal strategies used to treat headaches attributed to the menstrual cycle or to peri- or postmenopausal estrogen fluctuations. These may occur as a result of natural ovarian cycles, or in response to the withdrawal of exogenously administered estrogen.

BACKGROUND

A wide variety of evidence indicates that cyclic ovarian sex steroid production affects the clinical expression of migraine. This has led to interest in the use of hormonal treatments for migraine.

METHODS

A PubMed search of the literature was conducted using the terms "migraine,""treatment,""estrogen,""hormones,""menopause," and "menstrual migraine." Articles were selected on the basis of relevance.

RESULTS

The overarching goal of hormonal treatment regimens for migraine is minimization of estrogen fluctuations. For migraine associated with the menstrual cycle, supplemental estrogen may be administered in the late luteal phase of the natural menstrual cycle or during the pill-free week of traditional combination oral contraceptives. Modified contraceptive regimens may be used that extend the duration of active hormone use, minimize the duration or extent of hormone withdrawal, or both. In menopause, hormonally associated migraine is most likely to be due to estrogen-replacement regimens, and treatment generally involves manipulating these regimens. Evidence regarding the safety and efficacy of these regimens is limited.

CONCLUSIONS

Hormonal treatment of migraine is not a first-line treatment strategy for most women with migraine. Evidence is lacking regarding its long term harms and migraine is a contraindication to the use of exogenous estrogen in all women with aura and those aged 35 or older. The harm to benefit balances of several traditional nonhormonal therapies are better established.

Authors+Show Affiliations

Department of Neurology, Harvard Medical School, Boston, MA, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17300386

Citation

Loder, Elizabeth, et al. "Hormonal Management of Migraine Associated With Menses and the Menopause: a Clinical Review." Headache, vol. 47, no. 2, 2007, pp. 329-40.
Loder E, Rizzoli P, Golub J. Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache. 2007;47(2):329-40.
Loder, E., Rizzoli, P., & Golub, J. (2007). Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache, 47(2), 329-40.
Loder E, Rizzoli P, Golub J. Hormonal Management of Migraine Associated With Menses and the Menopause: a Clinical Review. Headache. 2007;47(2):329-40. PubMed PMID: 17300386.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormonal management of migraine associated with menses and the menopause: a clinical review. AU - Loder,Elizabeth, AU - Rizzoli,Paul, AU - Golub,Joan, PY - 2007/2/16/pubmed PY - 2007/4/18/medline PY - 2007/2/16/entrez SP - 329 EP - 40 JF - Headache JO - Headache VL - 47 IS - 2 N2 - OBJECTIVE: This article reviews hormonal strategies used to treat headaches attributed to the menstrual cycle or to peri- or postmenopausal estrogen fluctuations. These may occur as a result of natural ovarian cycles, or in response to the withdrawal of exogenously administered estrogen. BACKGROUND: A wide variety of evidence indicates that cyclic ovarian sex steroid production affects the clinical expression of migraine. This has led to interest in the use of hormonal treatments for migraine. METHODS: A PubMed search of the literature was conducted using the terms "migraine,""treatment,""estrogen,""hormones,""menopause," and "menstrual migraine." Articles were selected on the basis of relevance. RESULTS: The overarching goal of hormonal treatment regimens for migraine is minimization of estrogen fluctuations. For migraine associated with the menstrual cycle, supplemental estrogen may be administered in the late luteal phase of the natural menstrual cycle or during the pill-free week of traditional combination oral contraceptives. Modified contraceptive regimens may be used that extend the duration of active hormone use, minimize the duration or extent of hormone withdrawal, or both. In menopause, hormonally associated migraine is most likely to be due to estrogen-replacement regimens, and treatment generally involves manipulating these regimens. Evidence regarding the safety and efficacy of these regimens is limited. CONCLUSIONS: Hormonal treatment of migraine is not a first-line treatment strategy for most women with migraine. Evidence is lacking regarding its long term harms and migraine is a contraindication to the use of exogenous estrogen in all women with aura and those aged 35 or older. The harm to benefit balances of several traditional nonhormonal therapies are better established. SN - 0017-8748 UR - https://www.unboundmedicine.com/medline/citation/17300386/Hormonal_management_of_migraine_associated_with_menses_and_the_menopause:_a_clinical_review_ L2 - https://doi.org/10.1111/j.1526-4610.2006.00710.x DB - PRIME DP - Unbound Medicine ER -